Physician profile
Brian Song
NPI 1215578976
$4,509.66
in general payments reported to CMS, 2019-2025
23 companies · $1,490 in 2025
The $1,490 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $424 · 2022: $449 · 2023: $1,049 · 2024: $1,097 · 2025: $1,490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,233 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $250 · Consulting Fee: $150 · Education: $3.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,233.04 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $250.00 |
| Consulting Fee | $150.00 |
| Education | $3.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $757.08 | 2021-2025 | Emgality, Reyvow, Kisunla |
| Abbvie INC. | $744.96 | 2021-2025 | |
| Lundbeck LLC | $678.51 | 2022-2025 | Vyepti, Rexulti |
| Sk Life Science, INC. | $348.95 | 2021-2025 | Xcopri |
| Biogen, INC. | $287.62 | 2021-2025 | Tysabri, Vumerity, Avonex |
| Teva Pharmaceuticals USA, INC. | $274.41 | 2023-2025 | Austedo Xr, Austedo Xr |
| Emd Serono, INC. | $247.41 | 2022-2025 | Mavenclad |
| Amgen INC. | $210.84 | 2021-2022 | |
| Pfizer INC. | $204.98 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $199.73 | 2024-2025 | Ingrezza |
| Biohaven Pharmaceuticals, INC. | $166.15 | 2021 | |
| Cycle Pharmaceuticals INC | $51.92 | 2025 | Tascenso Odt, Bafiertam |
| Neurelis, INC. | $47.82 | 2023-2025 | Valtoco |
| Eisai INC. | $44.83 | 2025 | |
| Genentech USA, INC. | $44.11 | 2025 | Ocrevus Zunovo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $41.67 | 2025 | Ponvory |
| Novartis Pharmaceuticals Corporation | $34.71 | 2021-2025 | |
| Argenx US, INC. | $30.79 | 2025 | Vyvgart Hytrulo |
| Acadia Pharmaceuticals INC | $22.69 | 2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $20.13 | 2025 | Crexont |
| Mdd US Operations, LLC | $20.10 | 2024 | Apokyn |
| Otsuka America Pharmaceutical, INC. | $15.92 | 2025 | Rexulti |
| Ucb, INC. | $14.33 | 2025 | Rystiggo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Song listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.